Berkeley Lights, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Berkeley Lights, Inc. (BLI) operates as a digital cell biology company that enables and accelerates the development and commercialization of biotherapeutics and other cell-based products through its proprietary integrated platform; the platform comprises OptoSelect chips, reagent kits, advanced automation systems including the Beacon and Lightning platforms, and application and workflow software for rapid functional characterization of single cells at scale. The company provides solutions for antibody discovery, T-cell profiling, cell line development, high-throughput screening, automated cell culture, and data analytics, serving biopharma, diagnostics, and life science research customers such as top pharmaceutical firms and comprehensive cancer centers. Founded in 2011 and headquartered in Emeryville, California, Berkeley Lights conducts operations in North America, Asia Pacific, and Europe. In March 2023, the company completed its acquisition of IsoPlexis Corporation in an all-stock transaction valued at $57.8 million, forming PhenomeX Inc. (Nasdaq: CELL) with an expanded portfolio including IsoLight and IsoSpark proteomic systems, over 400 installed instruments, combined 2022 revenues of approximately $95 million, and $70 million in targeted cost synergies; PhenomeX was subsequently acquired by Bruker Corporation in October 2023 for $108 million in cash, integrating its technologies into Bruker Cellular Analysis as a wholly owned subsidiary focused on functional single-cell biology across discovery, bioprocessing, and translational research.
Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company
Berkeley Lights, Inc. (BLI) Q4 2022 Earnings Call Transcript
Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results
ISOPLEXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IsoPlexis Corporation - ISO
Berkeley Lights to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Berkeley Lights, Inc. (BLI) and Encourages Long-Term BLI Investors to Contact the Firm
SHAREHOLDER ALERT: Weiss Law Investigates IsoPlexis Corporation
Berkeley Lights Reports Preliminary Full Year 2022 Revenue Results
Berkeley Lights Launches Beacon Select™, A New Optofluidic System For Cell Line Development
Berkeley Lights Generates Further Losses Amid Merger Plan
Berkeley Lights to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BLI STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Berkeley Lights, Inc. Is Fair to Shareholders
BLI STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Berkeley Lights, Inc. Is Fair to Shareholders
Berkeley Lights to Showcase its New Beacon® System Workflow to Access Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies at 2022 Antibody Engineering & Therapeutics Conference
Berkeley Lights Accelerating Antibody Discovery with Launch of Rabbit Memory B Cell Workflow
Best Penny Stocks To Buy Now That CPI Is Out? 4 To Watch Before Next Week
Monash University Implements Antibody Discovery Application by Utilizing the Berkeley Lights Beacon® Platform
Berkeley Lights, Inc. (BLI) Q3 2022 Earnings Call Transcript
Berkeley Lights Reports Third Quarter 2022 Financial Results
Berkeley Lights to Host Upcoming Investor Day